An interventional study of 2 chewable tablets of MetaCalm and 4 chewable tablets of MetaCalm in Adults and Acute Stress Reaction, sponsored by Metagenics, Inc.. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Metagenics, Inc. · Not applicable, Interventional, and Supportive care
This Open-Label, Non-Randomized Clinical Study involving 280 participants who will undergo a total participation of 6 hours.
The trial begins with a screening process to assess eligibility for the study. Participants will then receive 2 or 4 MetaCalm chewable tablets, followed by a 6-hour phase during which they will be asked to complete several questionnaires at different times after taking the tablets.
58 studies on the registry are indexed under Stress Disorders, Traumatic, Acute; 15 are open to participants now.
This study's planned enrollment of 280 is above the median of 91 across 52 interventional studies indexed under Stress Disorders, Traumatic, Acute.
Browse Stress Disorders, Traumatic, Acute studies →Metagenics, Inc. is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Selection, during which eligibility to participate in the trial takes place at the start of the study: A single dose of 2 chewable tablets is administered.
Dietary Supplement: 2 chewable tablets of MetaCalm
Selection, during which eligibility to participate in the trial takes place at the start of the study: A single dose of 4 chewable tablets is administered.
Dietary Supplement: 4 chewable tablets of MetaCalm
2 chewable tablets is administered orally at time T0 (during an episode of acute stress).
4 chewable tablets is administered orally at time T0 (during an episode of acute stress).
STAI (State-Trait-Anxiety-Inventory) questionnaire
To assess the impact of MetaCalm on stress using a validated questionnaire, the State-Trait Anxiety Inventory (STAI) for adults. Depending on the patient's stress levels, scores will range from 10 to 40. The higher the score, the more stressed the patient is considered to be.
Time frame: 5 measurements in 6 hours
Hunger, appetite and craving impacts
Assess the effect of MetaCalm on hunger, appetite and the urge to snack using questions asked over a 6-hour period. Depending on your answers, scores will range from 7 to 45. The higher the score, the greater your hunger, appetite and urge to snack will be.
Time frame: 5 measurements in 6 hours
Side effects experienced when taking the test product throughout the study (product tolerance)
The proportion of participants at 6 hours (T4) that expressed any of the following symptoms
Time frame: At the of of the study, 6 hours after product administration
Patient satisfaction with product use and recommendation
The proportion of participants that at 6 hours (T4)
Time frame: At the of of the study, 6 hours after product administration
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Jun 2026, 2 months later.
Of 25 interventional studies with no phase under Stress Disorders, Traumatic, Acute, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Traumatic, Acute →
Metagenics, Inc.